

Nirmal Shah *Editor*

Nanocarriers: Drug Delivery System

An Evidence Based Approach

Nirmal Shah
Editor

Nanocarriers: Drug Delivery System

An Evidence Based Approach

Editor

Nirmal Shah

Department of Pharmacy

Sumandeep Vidyapeeth Deemed to be

University

Piparia, Vadodara, Gujarat, India

ISBN 978-981-33-4496-9

ISBN 978-981-33-4497-6 (eBook)

<https://doi.org/10.1007/978-981-33-4497-6>

© Springer Nature Singapore Pte Ltd. 2021

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.

The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore

Contents

Part I Targeted Drug Delivery


- 1 Fundamentals of Nanocarriers and Drug Targeting 3**
Dhiren P. Shah
- 2 Role of Lipid Nanocarriers in Lymphatic Targeting: Promises and Safety Considerations 43**
Jagruti L. Desai and Hetal P. Thakkar

Part II Nanoparticulate Drug Delivery Carriers

- 3 Synthesis, Pharmacokinetics, and Toxicity of Nano-Drug Carriers 63**
Noah Tedla, Jose Ruiz, Vicky Mody, Xinyu Wang, and Vishakha S. Bhave
- 4 Nanostructured Lipid Carriers (NLCs): A Modern Versatile Drug Delivery Vehicle 107**
Nirmal Shah, Dipti Gohil, and Snehal Patel
- 5 Nanocapsules 125**
Chintan J. Aundhia
- 6 Nanodiamonds for Theragnostic: Manufacturing and Biomedical Applications 139**
Dhrumi Patel and Sarika Wairkar
- 7 Evaluation of Nanotoxicity Using Zebrafish: Preclinical Model 173**
Rajesh A. Maheshwari, Dhanya B. Sen, Aarti S. Zanwar, and Ashim Kumar Sen

Part III Nanovesicular Drug Delivery Carriers

- 8 Niosomes: A Novel Nanometric Vesicular System for Drug Delivery 201**
Pranav Shah, Rinkal Jariwala, Swinal Kapadiya, Vidya P. Sabale, Priya Patel, and Pallavi M. Chaudhari



Nanocarriers: Drug Delivery System pp 201–226

Niosomes: A Novel Nanometric Vesicular System for Drug Delivery

[Pranav Shah](#) , [Rinkal Jariwala](#), [Swinal Kapadiya](#), [Vidya P. Sabale](#), [Priya Patel](#) & [Pallavi M. Chaudhari](#)

Chapter | [First Online: 23 January 2021](#)

458 Accesses | **1** [Citations](#)

Abstract

Vesicular systems like niosomes, liposomes, transferosomes, pharmacosomes, and ethosomes have been employed as an all-rounder tool to upgrade the delivery of drug, since the past decade.

Niosomes are submicron-sized vesicular drug delivery systems including nonionic surfactants, which are perishable, inexpensive, steadier, and relatively nontoxic in nature. There are various methods, which are meant for the preparation of niosomes. Niosomes are capable of delivering the drug in accordance with a predetermined rate and release therapeutically effective amount of drug at the targeted site. Various nonionic surfactants have been employed in the development of bilayer structure of niosomes. They have been known to

possess the merits of drug targeting in a controlled or sustained manner, long shelf life, and high stability. In recent years, the potential of niosomes, as a carrier for delivery of therapeutic agents, diagnostic agents, and biotechnology-based products like DNA and RNA, has been widely studied. This review acknowledges us regarding the techniques of formulation, characterization process, and recent utilization of niosomes in the delivery of drugs.

Keywords

- Niosomes Vesicular systems Drug delivery
- Drug targeting Nonionic surfactants
- Bilayer structure

This is a preview of subscription content, [access via your institution.](#)

▼ Chapter

EUR 29.95

Price includes VAT (India)

- DOI: 10.1007/978-981-33-4497-6_8
- Chapter length: 26 pages
- Instant PDF download
- Readable on all devices
- Own it forever
- Exclusive offer for individuals only
- Tax calculation will be finalised during checkout

Buy Chapter

> eBook

EUR 128.39

> Softcover Book

EUR 159.99

>

[Learn about institutional subscriptions](#)

References

Abdelbary G, El-Gendy N (2008) Niosome-encapsulated gentamicin for ophthalmic controlled delivery. *AAPS PharmSciTech* 9:740–747

Abdelbary A, Essam T, Abd El-Salam RM et al (2011) Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin (antifungal). *Drug Dev Ind Pharm* 37:149–508

Abdelbary A, Salem F, Khallaf R (2015) Niosomal 5-fluorouracil gel for effective treatment of skin cancer; in-vitro and in-vivo evaluation. *Int J Drug Deliv* 7(4):223–232

Abd-Elbary A, El-laithy H, Tadros M (2008) Sucrose stearate-based proniosome derived niosomes for the nebulisable delivery of cromolyn sodium. *Int J Pharm* 357(1–2):189–198

Abdelkader H, Ismail S, Kamal A et al (2012a) Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models. *Int J Pharm* 432:1–10

Abdelkader H, Ismail S, Hussein A et al (2012b)
Conjunctival and corneal tolerability assessment of
ocular naltrexone niosomes and their ingredients
on the hen's egg chorioallantoic membrane and
excised bovine cornea models. *Int J Pharm* 432(1–
2):1–10

Abdelkader H, Wu Z, Al-Kassas R et al (2012c)
Niosomes and discosomes for ocular delivery of
naltrexone hydrochloride: morphological,
rheological, spreading properties and photo-
protective effects. *Int J Pharm* 433(1–2):142–148

Agarwal R, Katare O, Vyas S (2001) Preparation and
in vitro evaluation of liposomal/niosomal delivery
systems for antipsoriatic drug dithranol. *Int J
Pharm* 228(1):43–52

Agarwal S, Bakshi V, Vitta P et al (2004) Effect of
cholesterol content and surfactant HLB on vesicle
properties of niosomes. *Indian J Pharm Sci*
66(1):121–123

Ahmad S (2016) Current status and future
prospects of application specific engineered
nanocurcumin compounds. *Int J Pharm Pharm Sci*
9:3391–3451

Akhilesh D, Bini KB, Kamath JV (2012) Review on
span-60 based non-ionic surfactant vesicles

(niosomes) as novel drug delivery. Int J Pharm
Biomed Res 3:6–12

Alemi A, Zavar R, Haghirsadat F et al (2018)
Paclitaxel and curcumin coadministration in novel
cationic PEGylated niosomal formulations exhibit
enhanced synergistic antitumor efficacy. J
Nanobiotechnology 16(1):28

Anbarasan B, Rekha S, Elango K et al (2013)
Optimization of the formulation and *in vitro*
evaluation of capecitabine niosomes for the
treatment of colon cancer. Int J Pharm Sci Res
37:1504–1513

Arunothayanun P, Bernard MS, Craig DQ et al
(2000) The effect of processing variables on the
physical characteristics of nonionic surfactant
vesicles (niosomes) formed from hexadecyl
diglycerol ether. Int J Pharm 201:7–14

Azmin M, Florence A (1987) The effect of non-ionic
surfactant vesicle (niosome) entrapment on the
absorption and distribution of methotrexate in
mice. J Microencapsul 4(4):321–328

Azmin MN, Florence AT, Handjani-Vila RM et al
(1985) The effect of non-ionic surfactant vesicle
(niosome) entrapment on the absorption and

distribution of methotrexate in mice. *J Pharm Pharmacol* 37:237–242

Baillie AJ, Florence AT, Hume LR et al (1985) The preparation and properties of niosomes-non-ionic surfactant vesicles. *J Pharm Pharmacol* 37:863–868

Baillie AJ, Coomb GH, Dolan TF et al (1986) Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. *J Pharm Pharmacol* 38:502–505

Bandyopadhyay P, Johnson M (2007) Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release. *Colloids Surf B Biointerfaces* 58(1):68–71

Barani M, Mirzaei M, Mahani M et al (2019) Evaluation of carum-loaded niosomes on breast cancer cells: physicochemical properties, in vitro cytotoxicity, flow cytometric, DNA fragmentation and cell migration assay. *Sci Rep* 9:7139

Bayindir ZS, Yuksel N (2010) Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. *J Pharm Sci* 99(4):2049–2060

Bayindir Z, Besikci A, Yuksel N (2015) Paclitaxel-

loaded niosomes for intravenous administration:
pharmacokinetics and tissue distribution in rats.
Turk J Med Sci 45(6):1403–1412

Beduneau A, Saulnier P, Hindre F et al (2007)
Design of targeted lipid nanocapsules by
conjugation of whole antibodies and antibody Fab'
fragments. *Biomaterials* 28:4978–4990

Bragagni M, Mennini N, Furlanetto S et al (2014)
Development and characterization of
functionalized niosomes for brain targeting of
dynorphin-B. *Eur J Pharm Biopharm* 87(1):73–79

Byrne J, Betancourt T, Brannon L (2008) Active
targeting schemes for nanoparticle systems in
cancer therapeutics. *Adv Drug Deliv Rev*
60(15):1615–1626

Chajed S, Sangle S, Barhate S (2011) Advantageous
nasal drug delivery system: a review. *Int J Pharm
Sci Res* 2(6):1322–1336

Christine D, Frederic B, Gaillard C (2004) Glucose-
targeted niosomes deliver vasoactive intestinal
peptide (VIP) to the brain. *Int J Pharm* 285:77–85

Dalia S, Shaker A, Hanafy M (2015) Cellular uptake,
cytotoxicity and in-vivo evaluation of Tamoxifen

citrate loaded niosomes. *Int J Pharm* 493(1–2):285–294

Danhier F, Feron O, Pr  at V et al (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *J Control Release* 148(2):135–146

Diljyot K (2012) Niosomes: a new approach to targeted drug delivery. *Int J Pharm Phytopharm Res* 2(1):53–59

Dufes C, Gaillard F, Uchegbu IF et al (2004) Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. *Int J Pharm* 285(1–2):77–85

Dwivedi A, Mazumder A, Plessis L et al (2015) In vitro anti-cancer effects of artemisone nano-vesicular formulations on melanoma cells. *Nanomedicine* 11:2041–2050

El-Ridy MS, Abdelbary A, Nasr EA et al (2011) Niosomal encapsulation of the antitubercular drug, pyrazinamide. *Drug Dev Ind Pharm* 37:1110–1118

Gaber M (2003) Enhanced cell killing by methotrexate encapsulated in folate targeted

thermosensitive liposomes. *Rom J Biophys* 13:31–41

Gandhi A, Sen S, Paul A (2012) Current trend in niosome as vesicular drug delivery system. *Asian J Pharm Life Sci* 2:339–353

Gharbavi M, Jafar A, Kheiri-Manjili H et al (2018) Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier. *Adv Pharmacol Sci* 2018:1–15

Gupta M, Vaidya B, Mishra N et al (2011) Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. *Artif Cells Blood Substit Immobil Biotechnol* 39:376–384

Handjani-vila RM, Ribier A, Vanlerberghe G (1982) Les liposomes. In: Lavoisier (ed) *Les liposomes*. Paris, pp 297–313

Hathout RM, Mansour S, Mortada ND, Guinedi AS (2007) Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. *AAPS PharmSciTech* 8:E1–E12

Hofland HE, Bouwstra JA, Ponec M et al (1991) Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: a survey of toxicological aspects and ultra-structural

changes in stratum corneum. *J Control Release* 16(1–2):55–167

Hong M, Zhu S, Jiang Y et al (2009) Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. *J Control Release* 133:96–102

Huang YZ, Han G, Wang H et al (2005) Cationic niosomes as gene carriers: preparation and cellular uptake in vitro. *Pharmazie* 60:473–474

Huang YZ, Gao JQ, Chen JL et al (2006) Cationic liposomes modified with non-ionic surfactants as effective non-viral carrier for gene transfer. *Colloids Surf B Biointerfaces* 49:158–164

Ingvarsson PT, Yang M, Nielsen HM et al (2011) Stabilization of liposomes during drying. *Expert Opin Drug Deliv* 8:375–388

Jadon PS, Gajbhiye V, Jadon RS et al (2009) Enhanced oral bioavailability of griseofulvin via niosomes. *AAPS PharmSciTech* 10(4):1186–1192

Jain CP, Vyas SP (1995) Preparation and characterization of niosomes containing rifampicin for lung targeting. *J Microencapsul* 12(4):401–407

Jiao J (2008) Poly oxy ethylated nonionic

surfactants and their applications in topical ocular drug delivery. *Adv Drug Deliv Rev* 60(15):1663–1673

Jia-You F, Chi-Tzong H, Wen-Ta C et al (2001) Effect of liposomes and niosomes on skin permeation of enoxacin. *Int J Pharm* 219:61–72

Junyaprasert VB, Teeranachaideekul V, Supaperm T (2012) Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. *AAPS PharmSciTech* 9(3):851–859

Kanaani L, Tabrizi MM, Khiyavi AA et al (2017) Improving the efficacy of cisplatin using niosome nanoparticles Against human breast cancer cell line BT-20: An In Vitro Study. *APJCB* 2(2):27-29

Kalra N, Jeyabalan G (2017) Formulation and in-vitro evaluation of niosomal drug delivery in cancer chemotherapy. *Indian J Pharm Biol Res* 5(4):29–33

Karki R, Mamatha GC, Subramanya G et al (2008) Preparation, characterization and tissue disposition of niosomes containing isoniazid. *Rasayan J Chem* 1:224–227

Karthick K, Kumaran K (2016) Formulation and

preclinical evaluation of niosomes co-loaded with 5-fluorouracil and leucovorin. *Int J Res Pharm Nano Sci* 5(5):283–292

Kaur D, Kumar S (2018) Niosomes: present scenario and future aspects. *J Drug Deliv Therap* 8(5):35–43

Kazi KM, Mandal AS, Biswas N et al (2010) Niosome: a future of targeted drug delivery systems. *J Adv Pharm Tech Res* 1:374–380

Keservani RK, Sharma AK, Ayaz MD (2011) Novel drug delivery system for the vesicular delivery of drug by the niosomes. *Int J Res Control Release* 1:1–8

Khaksa G, D'Souza R, Lewis S et al (2000) Pharmacokinetic study of niosome encapsulated insulin. *Indian J Exp Biol* 38:901–905

Kisan RJ, Manoj NG, Ishaque MS et al (2007) Nasal drug delivery system-factors affecting and applications. *Curr Drug Ther* 2:27–38

Kopermsuba P, Mayena V, Warin C (2011) Potential use of niosomes for encapsulation of nisin and EDTA and their antibacterial activity enhancement. *Food Res Int* 44:605–612

Kumar GP, Rajeshwarrao P (2011) Nonionic surfactant vesicular systems for effective drug delivery-an overview. *Acta Pharm Sin B* 1:208–219

Lanka (2019) What is the difference between liposomes and niosomes? <https://pediaa.com>. Accessed 27 June 2019

Laouini A, Jaafar C, Sfar S et al (2011) Liposome preparation using a hollow fiber membrane contactor application to spironolactone encapsulation. *Int J Pharm* 415:53–61

Lotfabadi AS (2019) Difference between liposomes and niosomes. <https://www.researchgate.net/post>. Accessed 18 June 2019

Mahato RI, Rolland A, Tomlinson E (1997) Cationic lipid-based gene delivery systems: pharmaceutical perspectives. *Pharm Res* 14:853–859

Manconi M, Valenti D, Sinico C et al (2003) Niosomes as carriers for tretinoin: II. Influence of vesicular incorporation on tretinoin photostability. *Int J Pharm* 260(2):261–272

Mandal S, Banerjee C, Ghosh S et al (2013) Modulation of the photophysical properties of curcumin in nonionic surfactant (Tween-20) forming micelles and niosomes: a comparative

study of different microenvironments. *J Phys Chem B* 117(23):6957–6968

Manpreet K, Kumar S (2018) Progress in the field of niosomes as novel drug delivery system. *Indo Am J Pharm Sci* 5(5):3417–3424

Marianecci C, Rinaldi F, Mastriota M et al (2012) Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. *J Control Release* 164(1):17–25

Mayer LD, Bally MB, Hope MJ (1985) Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. *Biochim Biophys Acta* 816(2):294–302

Medda S, Mukhopadhyay S, Basu MK (1999) Evaluation of the in vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. *J Antimicrob Chemother* 44:791–794

Mehta SK, Jindal N (2014) Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine. *AAPS PharmSciTech* 16(1):67–75

Meisnera D, Mezeib M (1995) Liposome ocular delivery systems. *Adv Drug Deliv Rev* 16:75–93

Mensah K, Oosthuizen F, Bonsu A (2018) Cancer awareness among community pharmacist: a systematic review. *BMC Cancer* 18:299

Mills J, Needham D (1999) Targeted drug delivery. *Expert Opin Ther Patents* 9:1499–1513

Mintzer MA, Simanek EE (2009) Nonviral vectors for gene delivery. *Chem Rev* 109:259–302

Moghassemi S, Hadjizadeh A (2014) Nano-niosomes as nano scale drug delivery systems: an illustrated review. *J Control Release* 185(1):22–36

Naresh RA, Chandrashekhar G, Pillai GK et al (1994) Anti-inflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. *Indian J Pharmacol* 26(1):46–48

Nasseri B (2005) Effect of cholesterol and temperature on the elastic properties of niosomal membranes. *Int J Pharm* 300(1):95–101

Ning M, Guo Y, Pan H et al (2005) Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. *Drug Dev Ind Pharm* 31:375–383

Nowroozi F, Dadashzadeh S, Soleimanjahi H et al (2018) Theranostic niosomes for direct

intratumoral injection: marked enhancement in tumor retention and anticancer efficacy.

Nanomedicine 13(17):2201–2219

Okore VC, Attama AA, Ofokansi KC et al (2011) Formulation and evaluation of niosomes. Indian J Pharm Sci 73(3):323–328

Paolino D, Cosco D, Muzzalupo R et al (2008) Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 353:233–242

Pardakhty A, Varshosaz J, Rouholamini A (2007) In vitro study of poly oxy ethylene alkyl ether niosomes for delivery of insulin. Int J Pharm 328(2):130–141

Parthasarathi G, Udupa N, Umadevi P et al (1994) Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J Drug Target 2(2):173–182

Pawar S, Vavia P (2016) Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin. J Drug Target 24(1):68–79

Prager GW, Braga S, Bystricky B et al (2018) Global cancer control: responding to the growing burden,

rising costs and inequalities in access. *ESMO Open* 3(2):e000285

Priprem A, Limphirat W, Limsitthichaikoon S et al (2012) Intranasal delivery of nanosized melatonin encapsulated niosomes in rats. *Open Access Sci Rep* 1(4):232–237

Radha GV, Rani TS, Sarvani B (2013) A review on proniosomal drug delivery system for targeted drug action. *J Basic Clin Pharm* 4(2):42–48

Reddy B, Padman J, Voruganti S (2012) Niosomes as nanocarrier systems: a review. *Int J Pharm Sci Res* 3(6):1560–1568

Rogerson A, Cummings J, Willmott N et al (1988) The distribution of doxorubicin in mice following administration in niosomes. *J Pharm Pharmacol* 40:337–342

Ruckmani K, Jayakar B, Ghosal S (2000) Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. *Drug Dev Ind Pharm* 26(2):217–222

Sahin NO (2007) Niosomes as nano carrier systems. In: Mozafari MR (ed) *Nanomaterials and*

nanosystems for biomedical applications. Springer, Dordrecht, pp 67–82

Sambathkumar R, Sekharbabu V, Perumal P et al (2011) Development and evaluation of cefpodoxime proxetil niosomes using various sorbitan esters. *Res J Pharm Biol Chem Sci* 2:213–219

Sankhyan A, Pawar P (2012) Recent trends in niosome as vesicular drug delivery system. *J Appl Pharm* 2(6):20–32

Saravanan D, Popli H (1998) Preparation and evaluation of metronidazole-loaded niosomes in rats. *Pharm Pharmacol Commun* 4:485–487

Sarkar S, Mandal S, Sinha J et al (2002) Quercetin: critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. *J Drug Target* 10:573–578

Seleci D, Seleci M, Walter J et al (2016) Niosomes as nanoparticulate drug carriers: fundamentals and recent applications. *J Nanomater* 2016:1–13

Shah N (2016) Characterization, optimization and formulation of niosome containing naproxen. *J Biomed Pharm Res* 5(1):1–6

Shaikh K, Pawar A, Aphale S et al (2012) Effect of vesicular encapsulation on in-vitro cytotoxicity of ciclopirox olamine. *Int J Drug Deliv* 4(2):139–146

Shaker D, Shaker M, Hanafy M (2015) Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. *Int J Pharm* 493:285–294

Shakya V, Bansal BK (2014) Niosomes: a novel trend in drug delivery. *Int J Res Dev Pharm Life Sci* 3(4):1036–1041

Sharma V, Anandhakumar S, Sasidharan M (2015) Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. *Mater Sci Eng C Mater Biol Appl* 56:393–400

Sharma P, Saxena P, Jaswanth A et al (2016) Novel encapsulation of lycopene in niosomes and assessment of its anticancer activity. *J Bioequivalence Bioavailab* 8:224–232

Shi B, Fang C, You M et al (2005) Influence of PEG chain length on in vitro drug release and in vivo pharmacokinetics of hydroxycamptothecin (HCPT) loaded PEG-PHDCA niosomes. *J Chin Pharm* 40(21):1643–1646

Singh G, Dwivedi H, Saraf SK et al (2011) Niosomal delivery of isoniazid—development and characterization. *Trop J Pharm Res* 10:203–210

Sohrabi S, Haeri A, Mahboubi A et al (2016) Chitosan gel-embedded moxifloxacin niosomes: an efficient antimicrobial hybrid system for burn infection. *Int J Biol Macromol* 85:625–633

Sudimack J, Lee R (2000) Targeted drug delivery via the folate receptor. *Adv Drug Deliv Rev* 41(2):147–162

Szoka J, Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation. *Proc Natl Acad Sci U S A* 75(9):4194–4198

Talsma H, Van MJ, Steenbergen JC et al (1994) A novel technique for the one-step preparation of liposomes and nonionic surfactant vesicles without the use of organic solvents. Liposome formation in a continuous gas stream: the “bubble” method. *J Pharm Sci* 83(3):276–280

Tavano L, Gentile L, Oliviero Rossi C et al (2013a) Novel gel-niosome formulations as multicomponent systems for transdermal drug delivery. *Colloids Surf B Biointerfaces* 110:281–288

Tavano L, Muzzalupo R, Mauro L et al (2013b)

Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy.

Langmuir 29(41):12638–12646

Thompson R (2010) Preventing cancer: the role of food, nutrition and physical activity. J Fam Health Care 20(3):100–102

Tila D, Narjes S, Saeed G et al (2015) pH-sensitive, polymer modified, plasma stable niosomes: promising carriers for anti-cancer drugs. EXCLI J 14:21–32

Timmakondur S, Parthiban S, Prabu S et al (2011) Formulation and evaluation of paclitaxel niosome for its improved anti-cancer activity. Acta Pharm Sci 53(3):469–475

Torchilin VP (2000) Drug targeting. Eur J Pharm Sci 11:S81–S91

Torre L, Bray F, Siegel R et al (2015) Global cancer statistics. J Clin 65(2):87–108

Uchegbu IF, Vyas SP (1998) Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 172(1–2):33–70

Uchegbu I, Turton J, Double J et al (1994) Drug

distribution and a pulmonary adverse effect of intraperitoneally administered doxorubicin niosomes in the mouse. *Biopharm Drug Dispos* 15(8):691–707

Udupa N, Chandraprakash K, Umadevi P et al (1993) Formulation and evaluation of methotrexate niosomes. *Drug Dev Ind Pharm* 19:1331–1342

Vanani R, Karimian K, Azarpira N et al (2019) Capecitabine-loaded nanoniosomes and evaluation of anticancer efficacy. *Artif Cell Nanomed B* 47(1):420–426

Varshosaz J, Pardakhty A, Hajhashemi V et al (2003) Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. *Drug Deliv* 10:251–262

Vemuri S, Rhodes CT (1995) Preparation and characterization of liposomes as therapeutic delivery systems: a review. *Pharm Acta Helv* 70:95–111

Verma S, Singh S, Navneet S et al (2010) Nanoparticle vesicular systems: a versatile tool for drug delivery. *J Chem Pharm Res* 2(2):496–509

Vyas SP, Khar RK (2002) Controlled drug delivery—

concepts and advances, 1st edn. Vallabh
Prakashan, New Delhi, pp 38–50

Waddad AY, Abbad S, Yu F et al (2013)
Formulation, characterization and
pharmacokinetics of Morin hydrate niosomes
prepared from various non-ionic surfactants. *Int J
Pharm* 456(2):446–458

Waterman KC, Adami RC, Alsante KM et al (2002)
Stabilization of pharmaceuticals to oxidative
degradation. *Pharm Dev Technol* 7:1–32

Williams D, Mullen AB, Baillie AJ et al (1998)
Comparison of the efficacy of free and non-ionic-
surfactant vesicular formulations of paromomycin
in a murine model of visceral leishmaniasis. *J
Pharm Pharmacol* 50:1351–1356

Wiseman M (2019) Nutrition and cancer:
prevention and survival. *Br J Nutr* 122(5):481–487

Xu Y, Chen W, Tsosie J et al (2016) Niosome
encapsulation of Curcumin: characterization and
cytotoxic effect on ovarian cancer cells. *J
Nanomater* 2:1–9

Yang H, Deng A, Jingqing Z (2013) Preparation,
characterization and anticancer therapeutic

efficacy of cisplatin-loaded niosomes. J

Microencapsul 30(3):237–244

Yoshioka T, Sternberg B, Florence AT (1994)

Preparation and properties of vesicles (niosomes)

of sorbitan monoesters (Span 20, 40, 60 and 80)

and a sorbitan triester (Span 85). Int J Pharm

105(1):1–6

Yuksel N, Bayindir ZS, Aksakal E et al (2016) In situ

niosome forming maltodextrin proniosomes of

candesartan cilexetil: in vitro and in vivo

evaluations. Int J Biol Macromol 82:453–463

Zuidam NJ, Lee SS, Crommelin DJA (1993)

Sterilization of liposomes by heat treatment.

Pharm Res 10:1591–1596

Author information

Authors and Affiliations

Maliba Pharmacy College, Uka Tarsadia

University, Gopal Vidyanagar, Surat, Gujarat,

India

Pranav Shah, Rinkal Jariwala & Swinal Kapadiya

Dadasaheb Balpande College of Pharmacy, Besa,

Nagpur, Maharashtra, India

Vidya P. Sabale

Department of Pharmaceutical Sciences,

Saurashtra University, Rajkot, Gujarat, India

Priya Patel

Department of Pharmaceutics, Dr. D. Y. Patil

College of Pharmacy, Pune, Maharashtra, India

Pallavi M. Chaudhari

Corresponding author

Correspondence to [Pranav Shah](#).

Editor information

Editors and Affiliations

Department of Pharmacy, Sumandeep

Vidyapeeth Deemed to be University, Piparia,

Vadodara, Gujarat, India

Dr. Nirmal Shah

Rights and permissions

[Reprints and Permissions](#)

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Shah, P., Jariwala, R., Kapadiya, S., Sabale, V.P., Patel, P., Chaudhari, P.M. (2021). Niosomes: A Novel Nanometric Vesicular System for Drug Delivery. In: Shah, N. (eds) Nanocarriers: Drug Delivery System. Springer, Singapore. https://doi.org/10.1007/978-981-33-4497-6_8

[.RIS](#) [.ENW](#) [.BIB](#)

DOI

https://doi.org/10.1007/978-981-33-4497-6_8

Published	Publisher Name	Print ISBN
23 January 2021	Springer, Singapore	978-981-33- 4496-9

Online ISBN	eBook Packages
978-981-33- 4497-6	Chemistry and Materials Science Chemistry and Material Science (R0)

Not logged in - 117.222.52.255

Not affiliated

SPRINGER NATURE© 2022 Springer Nature Switzerland AG. Part of [Springer Nature](#).